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Abstract
Background: Hypertension is the most important single modifiable risk factor for stroke. We
investigated the distribution of stroke risk factors and 10-year probability of stroke in Korean
hypertensive patients.
Methods: A total of 1,402 hypertensive patients treated by cardiology departments at 37 general
hospitals nationwide were enrolled. Risk factors for stroke were evaluated using a series of
laboratory tests and physical examinations, and the 10-year probability of stroke was determined
by applying the Framingham stroke risk equation.
Results:  The proportion of patients who have uncontrolled hypertension despite use of
antihypertensives was 37.2% (37.2% women, 37.3% men, p = 0.990). The average 10-year
probability of stroke in hypertensive patients was 24.27% (24.17% women, 24.39% men, p = 0.825),
approximately 2.4 times higher than of the risk of stroke observed in the Korean Cancer
Prevention Study [KCPS] cohort. The 10-year stroke probability in patients with hypertension
increased in proportion to age. In patients for hypertension, the 10-year probability of stroke
increased in proportion to blood pressure.
Conclusion: Aggressive interventions are mandated to reduce blood pressure and alleviate the
high risk of stroke in hypertensive patients.
Background
Hypertension (HTN) is one of the most common chronic
diseases in adults. Major complications of HTN include
ischemic heart disease, stroke, heart failure, renal failure,
aortic and peripheral arterial diseases. Stroke is a leading
cause of death and disability among individuals older
than 65 years in Korea. The total number of deaths attrib-
utable to stroke in Korea is estimated at 13.9% and asso-
ciated annual medical costs account for more than 10% of
total medical expenditures [1,2]. In addition, stroke is
becoming a major cause of death and behavioral disor-
ders due to the rapidly aging Korean population [3].
Although various factors induce stroke, HTN and aging
are known to be most common risk factors of stroke
worldwide [4,5]. Aging is an irreversible factor, but HTN
is controllable. Appropriate treatment of HTN has been
shown to reduce the risk of stroke by 40% and the risk of
acute myocardial infarction by 15% [6]. According to
related research, an increase of systolic blood pressure
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(SBP) and diastolic blood pressure (DBP) 20/10 mmHg
from 115/75 mmHg doubles the risk of stroke [6].
The Framingham Study, a reliable prospective epidemiol-
ogy study on chronic diseases established in the United
States in 1948, revealed that risk factors of stroke include
age, SBP, use of anti-hypertensives, diabetes, smoking,
cardiovascular diseases (CVD), atrial fibrillation, and left
ventricular hypertrophy (LVH) [7-9]. The average 10-year
probability of stroke in the total Korean Cancer Preven-
tion Study (KCPS) cohort was 3.5% for males and 3.7%
for females, and the average 10-year probability of stroke
in the 55–84 years of age group within the KCPS cohort
was 10.0% for males and 9.0% for females [10]. Wolf et al.
showed that for each 10 mmHg increase in SBP, the risk
of stroke increased by 91% for men and 68% for women
[7]. Although hypertension is the most important single
modifiable risk factor for stroke, there is little data about
the practical 10 year stroke risk in hypertensive patients.
We reported previously that the 10-year risk of stroke in
Korean hypertensive patients visiting community-based
hospitals was approximately 4.6 times higher than of the
risk of stroke in of the KCPS cohort [11]. However, the
enrolled patients were limited to only patients visiting
community-based hospitals. Therefore, we planned to
evaluate the 10-year probability of stroke in Korean
hypertensive patients visiting tertiary hospitals using the
Framingham risk score [7].
Methods
Study population
We conducted a multicenter study evaluating patients
treated by the cardiology departments of 37 general hos-
pitals in Korea. Our study population included 1735
patients with HTN between 55 and 84 years of age. We
excluded 333 subjects due to a previous history of stroke.
Consequently, 1402 patients (769 male, 633 female) were
enrolled in the study. All subjects gave written informed
consent. This study was approved by the local ethics com-
mittee.
Laboratory and lifestyle factors measurement
Body weight and height were measured with subjects
wearing light clothing and without shoes. The body mass
index (BMI) was calculated as the weight in kilograms
divided by the height in meters squared. The waist circum-
ference was measured from the narrowest point between
the lower borders of the rib cage and the iliac crest.
Blood pressure was measured in the right arm, using an
appropriately sized cuff and a standard mercury sphyg-
momanometer, after the subjects had been seated for at
least 15 min, with feet on the floor and arm supported at
heart level.
Fasting blood samples were obtained in the morning after
at least 8 hours of fasting. Plasma glucose, total choles-
terol, triglyceride, high density lipoprotein (HDL)-choles-
terol, and low density lipoprotein (LDL)-cholesterol were
measured.
Risk factors for stroke were age, diabetes, smoking, medi-
cal history of cardiovascular disease, atrial fibrillation,
LVH, hyperlipidemia, alcohol intake, physical exercise,
obesity, and family history of stroke.
Antihypertensive medications that subjects were currently
receiving were classified as angiotensin converting
enzyme inhibitor (ACEI), angiotensin receptor blocker
(ARB), calcium channel blocker (CCB), beta-blocker
(BB), diuretics, and others.
Estimation of 10-year probability of stroke
The 10-year probability of stroke was estimated for each
patient using the Framingham risk score [7]. The variables
used to calculate the Framingham risk score are age, systo-
lic blood pressure, anti-hypertensive therapy, diabetes
mellitus, smoking, CVD, atrial fibrillation, and LVH.
Study definitions
We identified HTN with repeated measurements of ≥ 140
mmHg SBP or ≥ 90 mmHg DBP or previous diagnosis.
HTN stage was classified according to Joint National
Committee 7 (JNC-7) criteria [12]: normal (SBP < 120
mm Hg and DBP < 80 mm Hg); pre-HTN (120 ≤ SBP <
140 mm Hg or 80 ≤ DBP < 90 mm Hg); stage 1 (140 ≤ SBP
< 160 mm Hg or 90 ≤ DBP < 100 mm Hg); and stage 2
(SBP ≥ 160 or DBP ≥ 100 mm Hg). Uncontrolled HTN
was defined as repeated measurements of ≥ 140 mmHg
SBP and ≥ 90 mmHg DBP, despite use of antihyperten-
sives. Diabetes was defined as fasting blood glucose con-
centration ≥ 126 mg/dL or taking diabetes medications.
Subjects were classified as "non-smokers" (patients who
never smoked before and did not smoke currently) or
"smokers" (patients who had smoked within the past year
or who smoke currently). Atrial fibrillation was confirmed
by electrocardiogram. The product of QRS duration times
the Cornell voltage combination (RaVL + SV3, with 6 mm
added in women [13,14]) greater than 2440 mm/msec or
Sokolow-Lyon voltage (SV1 + RV5/6) greater than 38 mm
[15] was used to identify LVH.
CVD was defined as a combination of coronary artery dis-
ease (CAD) and congestive heart failure (CHF). CAD was
defined as any hospitalization for acute myocardial infarc-
tion or angina and CHF was defined as any hospitaliza-
tion for CHF. If a stroke had occured within a first line
relative, subjects were considered to have a family history
of stroke. Dyslipidemia was defined in terms of the fol-BMC Neurology 2009, 9:16 http://www.biomedcentral.com/1471-2377/9/16
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lowing criteria: total cholesterol > 200 mg/dL, triglyceride
> 150 mg/dL, HDL-cholesterol < 40 mg/dL, or LDL-cho-
lesterol > 100 mg/dL.
We use the definition of metabolic syndrome as proposed
by National Cholesterol Education Program Adult Treat-
ment Panel III [16]. Target organ damage variables were
serum creatinine (women > 1.2 mg/dL, men > 1.3 mg/
dL), LVH (electrocardiography criteria per Cornell, and/or
Sokolow-Lyon criteria [13,15]), microalbuminuria
(women ≥ 3.5 mg/mmol in women, men ≥ 2.5 mg/mmol
per 2003 guidelines of the European Society of Hyperten-
sion/European Society of Cardiology) [17], and retinal
lesions following Dodson's classification [18]. Renal func-
tion alteration was also calculated, using the Cockcroft
and Levey formulae, and expressed as a glomerular filtrate
< 60 ml/min.
Statistical analysis
Statistical analysis was performed using the SPSS 10.0
software package (SPSS Inc., Chicago, IL, USA). Continu-
ous variables were expressed as means ± S.D. and categor-
ical variables were reported as number (%). Continuous
variables were compared using Student's t-test, or one
way-ANOVA with post hoc multiple comparisons per-
formed using Duncan's (D) multiple comparison test.
Categorical variables were compared using a chi-square
test or Fisher's exact test. A p < 0.05 was considered statis-
tically significant.
Results
Baseline characteristics and risk factors
The baseline characteristics and risk factors of our subjects
are summarized in Table 1. Our sample included 633 men
and 769 women. The mean age of patients was 68.41 ±
7.40 years. The average SBP was 132 ± 17 mmHg and the
average DBP was 79 ± 10 mmHg. The prevalence of sub-
jects taken antihypertensives was 76.0% (76.9% women,
75.0% men, p = 0.429). The prevalence of subjects with
target organ damage was 16.3% (15.2% women, 17.5%
men, p = 0.241). The prevalence of diabetes mellitus was
16% (17.2% women, 14.7% men, p = 0.209) and the
prevalence of cigarette smoking was 30.6% (3.6%
women, 63.3% men, p < 0.001). The prevalence of CVD
Table 1: Characteristics of risk factors in study subjects
Female Male Total
Risk factors (n = 769) (n = 633) (n = 1402) p
Age, years 68.96 ± 7.36 67.74 ± 7.40 68.41 ± 7.40 0.002
Height, 154.50 ± 6.20 167.24 ± 5.79 160.44 ± 8.76 <0.001
Weight 60.63 ± 8.68 69.08 ± 9.23 64.56 ± 9.88 <0.001
Systolic blood pressure, mmHg 133 ± 17 131 ± 16 132 ± 17 0.143
Diastolic blood pressure, mmHg 79 ± 10 79 ± 10 79 ± 10 0.303
Heart rate 71 ± 11 71 ± 11 71 ± 11 0.648
Glucose 115.12 ± 34.14 113.62 ± 37.13 114.43 ± 377 0.491
Total cholesterol 201.32 ± 42.02 184.42 ± 41.03 193.56 ± 42.39 < 0.001
HDLc 49.52 ± 29.82 44.66 ± 12.43 47.28 ± 23.56 < 0.001
Triglyceride 159.85 ± 127.34 156.05 ± 108.74 158.08 ± 118.99 0.573
LDLc 132.00 ± 42.22 115.20 ± 42.10 12434 ± 42.96 < 0.001
Antihypertensives, n (%) 591 (76.9) 475 (75.0) 1066 (76.0) 0.429
Target organ damage, n (%) 117 (15.2) 111 (17.5) 228 (16.3) 0.241
Diabetes mellitus, n (%) 132 (17.2) 93 (14.7) 225 (16) 0.209
Diabetes mellitus medication, n (%) 152 (19.8) 103 (16.3) 255 (18.2) 0.091
Cigarette smoking, n (%) 28 (3.6) 401 (63.3) 429 (30.6) < 0.001
Cardiovascular disease, n (%) 365 (47.5) 329 (52.0) 694 (49.5) 0.093
Atrial fibrillation, n (%) 54 (7.0) 54 (8.5) 108 (7.7) 0.292
Left ventricular hypertrophy, n (%) 218 (28.3) 233 (36.8) 451 (32.2) 0.001
Dyslipidemia, n (%) 116 (16.6) 47 (7.9) 163 (12.6) < 0.001
Body mass index ≥ 25 kg/m2, n (%) 231 (30) 149 (23.5) 380 (27.1) 0.006
Stroke family history, n (%) 94 (12.2) 95 (15.0) 189 (13.5) 0.129
Antiplatelet therapy, n (%) 367 (47.7) 386 (61.0) 753 (53.7) < 0.001
Warfarin therapy, n (%) 22 (2.9) 17 (2.7) 39 (2.8) 0.743
Lipid lowering therapy, n (%) 238 (30.9) 167 (26.4) 405 (28.9) 0.06
Uncontrolled HTN, n (%) 277 (36) 229 (36.2) 506 (36.1) 0.736
10-year probability of stroke 24.17 ± 20.77 24.39 ± 17.03 24.27 ± 19.16 0.825
HDLc: High density lipoprotein-cholesterol, LDLc: Low density lipoprotein-cholesterol, cardiovascular disease: history of myocardial infarction, 
angina pectoris, coronary insufficiency, intermittent claudication, or congestive heart failure. Values: Mean ± SD or number (%). n: number.BMC Neurology 2009, 9:16 http://www.biomedcentral.com/1471-2377/9/16
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was 49.5% (47.5% women, 52.0% men, p = 0.093) and
the prevalence of atrial fibrillation was 7.7% (7.0%
women, 8.5% men, p = 0.292). The prevalence of LVH
was 32.2% (28.3% women, 36.8% men, p < 0.001).
Measurements of total cholesterol, HDL-cholesterol and
LDL-cholesterol measurements were higher in women
than in men. Prevalences of smoking, LVH, drinking, and
physical exercise were higher in men than in women. The
proportion of patients who had uncontrolled hyperten-
sion despite use of antihypertensives was 37.2% (37.2%
women, 37.3% men, p = 0.990; Figure. 1-A) The preva-
lence of metabolic syndrome according to the ATP-III
guideline was 28% (26.1% women, 30.5% men, p =
0.071; Figure 1-B).
Average 10-year probability of stroke
The average 10-year probability of stroke was 26.27%
(26.9% women, 25.5% men) (Table 1). As expected, 10-
year probability of stroke in patients with HTN increased
in proportion to age (Table 2). Figure 2-A illustrates differ-
ences in the average 10-year probability of stroke between
men and women according to age. Men aged 60–69 years
had a higher 10-year probability of stroke than women of
similar age. However, in other age groups, there were no
gender-related differences. Table 2 also showed the aver-
age 10-year probability of stroke according to blood pres-
sure in treated hypertensive patients. Differences in the
average 10-year probability of stroke between men and
women, according to HTN stage, are shown in Figure 2-B.
In HTN stage 2, the 10-year probability of stroke was high
in women compared to men. At all other HTN stages there
were no differences by gender.
As illustrated in Figure 3, the average 10-year probability
of stroke was higher in patients with metabolic syndrome
than in patients without metabolic syndrome.
Concomitant antihypertensives taken according to age 
(Table 3)
Physicians prescribed antihypertensives for hypertensive
patients was as follows: ARB 48.6%, CCB 38.7%, beta-
blocker 31.5%, ACEI 9.9%, diuretics 7.8%, combined
treatment 35.9%. Of these, only diuretics were prescribed
more frequently with increasing age, with the rest of these
medications showing no age-related presciption trends.
Discussion
This study is an initial report designed to predict the 10-
year probability of stroke in Korean hypertensive patients
visiting tertiary hospitals using the Framingham risk score.
We found the average 10-year probability of stroke in
hypertensive patients was 26.27% (26.9% women, 25.5%
men), which was approximately 2.4 times higher than val-
ues found in a previous study of the KCPS cohort [10].
This result may be explained by the fact that 34% of the
A: Proportion of patients with uncontrolled hypertension despite use of antihypertensives Figure 1
A: Proportion of patients with uncontrolled hypertension despite use of antihypertensives. Uncontrolled HTN 
was defined as repeated measurements of ≥ 140 mmHg SBP and ≥ 90 mmHg DBP, despite use of antihypertensives. B: Preva-
lence of metabolic syndrome in patients with hypertension.BMC Neurology 2009, 9:16 http://www.biomedcentral.com/1471-2377/9/16
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hypertensive patients did not take antihypertensives
(Table 1) and therefore their blood pressure was not well
controlled. Another possible explanation is that even
among hypertensive patients complying with treatment,
37.2% suffered from uncontrolled HTN (Figure 1-A). The
10-year probability of stroke increased in proportion to
blood pressure even among patients being treated for
hypertension (Table 2). These findings demonstrate that
stricter control of HTN may be an important intervention
for prevention of stroke.
In HTN stage 2, the 10-year probability of stroke was
higher in women compared to that of men, but in other
HTN stages, there was no difference between men and
women (Figure 2-B). Female patients in HTN stage 2, were
older than their male counterparts, but this difference was
not observed in other HTN stages. In addition, the distri-
butions of other risk factors did not segregate by gender at
any other stage of HTN (data not shown). Therefore, we
believe that the difference in the 10-year probability of
stroke between men and women for HTN stage 2 is related
to age.
The 10-year probability of stroke in HTN patients
increased in proportion to age (Table 2) but the distribu-
tion of 10-year probability of stroke between men and
Table 2: Average 10-year probability of stroke according to age in all subjects and blood pressure in treated hypertensive patients.
Age group 10 year risk of Stroke* Stage of HTN 10 year risk of Stroke*
< 60 (n = 167) 12.42 ± 9.11a Normal (n = 134) 21.16 ± 17.23a
60–69 (n = 654) 18.63 ± 13.89b Prehypertension (n = 535) 26.57 ± 18.92b
70–79 (n = 467) 31.10 ± 20.42c Stage 1 HTN (302) 29.15 ± 19.48b
> 79 (n = 114) 46.00 ± 23.15d Stage 2 HTN (95) 36.22 ± 23.74c
P** < 0.001 P** <0.001
* Mean ± standard deviation
**P-value is for one-way analysis of variance
a,b,c, same letters indicate statistical insignificance based on Duncan's multiple comparisons. Normal: SBP < 120 mm Hg and DBP < 80 mm Hg, pre-
hypertension: 120 ≤ SBP < 140 mm Hg or 80 ≤ DBP < 90 mm Hg, stage 1: 140 ≤ SBP < 160 mm Hg or 90 ≤ DBP < 100 mm Hg, stage 2: SBP ≥ 160 
or DBP ≥ 100 mm Hg.
A: The average 10-year risk of stroke according to age in men and women with hypertension Figure 2
A: The average 10-year risk of stroke according to age in men and women with hypertension. B: The difference in 
average 10-year probability of stroke between men and women, according to HTN stage. Normal is SBP < 120 mmHg and 
DBP < 80 mmHg, Pre-hypertension is 120 ≤ SBP < 140 mmHg or 80 ≤ DBP < 90 mmHg, HTN stage 1 is 140 ≤ SBP < 160 
mmHg or 90 ≤ DBP < 100 mmHg, HTN stage 2 is SBP ≥ 160 or DBP ≥ 100 mmHg.BMC Neurology 2009, 9:16 http://www.biomedcentral.com/1471-2377/9/16
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women varied according to age. In the 60–69 year age
group, the 10-year probability of stroke was higher for
men than for women, but in other age groups there was
no difference by gender (Figure 2-A). In the 60–69 year
age group, frequencies of history of CVD and LVH were
higher for men than for women, but not in other age
groups. The distribution of other risk factors between men
and women did not differ according to age (data not
shown). Therefore, we believe that differences in the 10-
year probability of stroke between men and women in
aged 60–69 are driven by the distribution of CVD and
LVH.
The prevalence of diabetes mellitus in hypertensive
patients was 16% (17.2% women, 14.7% men; Table 1),
which was higher than that seen in the Korean National
Health and Nutrition Examination Survey [19]. This study
showed that, in the Korean population, the prevalence of
diabetes mellitus was 9.1% (7.9% women, 10.2% men).
Our enrolled subjects were older and considered high risk
patients, which may explain the discrepancy.
The prevalence of dyslipidemia in our sample of hyper-
tensive patients was 12.6% (7.9% women, 16.6% men;
Table 1). This prevalence was lower than that observed by
the Korean National Health and Nutrition Examination
Survey (2005) [19]. That study showed that, in the general
Korean population, the prevalence of dyslipidemia was
48.3% (38.2% women, 58.9% men). Our enrolled sub-
jects were older and considered high risk patients, and had
been prescribed anti-lipid lowering agents, which may
explain the discrepancy.
The prevalence of metabolic syndrome in our sample of
hypertensive patients measured according to the ATP-III
guideline was 28% (26.1% women, 30.5% men; Figure 1-
B). This result was similar to values found by the Korean
National Health and Nutrition Examination Survey
(2005) [19]. That study showed that, in the general
Korean population, the prevalence of metabolic syn-
drome was 29.5% (26.1% women, 33.1% men). Another
report suggests that metabolic syndrome is an important
risk factor for ischemic stroke [20]. According to our
results, the 10-year risk of stroke is higher for patients suf-
fering from metabolic syndrome (Figure 3).
In Korea, ARB was the most frequently prescribed antihy-
pertensive at 48.6%, with the next being CCB (38.7%).
Cardiologists working at general hospitals tend to prefer
ARB to other antihypertensives due to higher compliance
and fewer side effects., Many clinical papers demonstrat-
ing positive effects of ARB for the prevention of stroke and
cardiovascular diseases have been published recently [21].
The prescription frequency of ACEI was only 9.9%, prob-
ably due to side effects such as cough, and a general pref-
erence for ARB. Diuretics were more frequently prescribed
for older patients than for younger patients. This may be
due to a high prevalence of complications, such as
ischemic heart disease and heart failure, in older patients.
The average 10-year risk of stroke according to metabolic  syndrome Figure 3
The average 10-year risk of stroke according to met-
abolic syndrome.
Table 3: Concomitant antihypertensives according to age
Drug, n (%) < 60 60–69 70–79 > 79 Total
(n = 167) (n = 654) (n = 467) (n = 114) (n = 1402) p
ACEI 25 (15.0) 53 (8.1) 48 (10.3) 13 (11.4) 139 (9.9) 0.057
ARB 76 (45.5) 325 (49.7) 220 (47.1) 60 (52.6) 681(48.6) 0.55
BB 49 (29.3) 203 (31.0) 156 (33.4) 34 (29.8) 442 (31.5) 0.716
CCB 66 (39.5) 261 (39.9) 176 (37.7) 39 (34.2) 542 (38.7) 0.655
Diuretics 9 (5.4) 39 (6.0) 52 (11.1) 10 (8.8) 110 (7.8) 0.008
Combined Antihypertensives 55 (32.9) 222 (33.9) 183 (39.2) 43 (37.7) 503 (35.9) 0.253
ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker, BB: beta-blocker, CCB: calcium channel blocker. Combined 
antihypertensive treatment: take more than two antihypertensive drugs.BMC Neurology 2009, 9:16 http://www.biomedcentral.com/1471-2377/9/16
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Among Korean hypertensive patients, 35.9% took more
than two antihypertensive drugs (Table 3). This frequency
was similar to that in seen in the United States (35.8%,
1999–2002) [22].
In our study, 76% of hypertensive patients took antihy-
pertensive medication and 63.9% of patients on antihy-
pertensive medication had controlled HTN (Table 1).
These results were high compared to those found by the
Korean National Health and Nutrition Examination Sur-
vey (2005) [19], but this may be explained by the fact that
our study population was derived from a highly selected
group of patients who were visiting cardiology clinics for
suspected or established cardiac diseases.
This study has some limitations. First, our study popula-
tion was derived from a highly selected group of patients
who were visiting tertiary hospitals for suspected or estab-
lished cardiac diseases. Although it is appropriate to do a
collective study with the cooperation of community based
hospitals, public health centers, and general hospitals, our
study included only tertiary hospitals. Therefore, cardio-
vascular risk factors are overrepresented in our sample.
Second, this study was a simple cross-sectional study and
did not consider information about practical stroke
events. Therefore, we could not compare 10-year proba-
bility of stroke with real stroke incidence. Third, we did
not directly compare the 10-year probability of stroke for
our hypertensive sample and the KCPS cohort [10].
Fourth, we assessed smoking status with a single, self-
reported questionnaire. Therefore, non-differential mis-
classification is possible.
Conclusion
In conclusion, the average 10-year probability of stroke in
our hypertensive sample was 26.27%, and this level was
approximately 2.4 times higher than that seen in the KCPS
cohort. The probability of stroke in our sample increased
with severity of blood pressure in treated hypertensive
patients. We suggest that stricter control of HTN may
prove to be an important intervention for preventing
stroke.
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